European surgeon training announcement for GelrinC drives RGNT

 

European surgeon training announcement for GelrinC drives RGNT 137% premarket surge

• Regentis issued June 8 PR detailing Q3 2026 start of hands-on EU surgeon training for CE Mark-approved GelrinC hydrogel implant.
• Training begins at Humanitas Research Hospital in Milan; additional sessions and Centers of Excellence planned across Europe.
• News marks key step accelerating commercial launch preparations for off-the-shelf knee cartilage repair product.
• Low-float nano-cap stock (post-Dec 2025 IPO at $8, recent ~$1.28 close) reacted sharply to positive commercialization update.
• After-hours/premarket trading pushed shares from $1.28 close to ~$3.00–$3.30 range (+127–160%), with elevated volume.
• Builds on prior EU collaboration with Humanitas and manufacturing improvements; no other major catalyst identified.
• Retail momentum amplified move in this small-cap regenerative medicine name per forum and news coverage.

https://finviz.com/stock?t=RGNT&p=d